BG63153B1 - Метод за получаване на протеинов хидролизат и използването му за предотвратяване или лечение на алергии - Google Patents
Метод за получаване на протеинов хидролизат и използването му за предотвратяване или лечение на алергии Download PDFInfo
- Publication number
- BG63153B1 BG63153B1 BG102144A BG10214497A BG63153B1 BG 63153 B1 BG63153 B1 BG 63153B1 BG 102144 A BG102144 A BG 102144A BG 10214497 A BG10214497 A BG 10214497A BG 63153 B1 BG63153 B1 BG 63153B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- lactobacillus
- atcc
- bacteria
- protein hydrolyzate
- bacterial preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 29
- 239000003531 protein hydrolysate Substances 0.000 title claims abstract description 25
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 16
- 230000007815 allergy Effects 0.000 title claims abstract description 8
- 230000002265 prevention Effects 0.000 title claims abstract 3
- 108010009736 Protein Hydrolysates Proteins 0.000 title abstract description 3
- 241000186660 Lactobacillus Species 0.000 claims abstract description 64
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 46
- 241000894006 Bacteria Species 0.000 claims abstract description 41
- 102000004190 Enzymes Human genes 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 23
- 229940088598 enzyme Drugs 0.000 claims abstract description 23
- 239000006041 probiotic Substances 0.000 claims abstract description 21
- 235000018291 probiotics Nutrition 0.000 claims abstract description 21
- 230000000529 probiotic effect Effects 0.000 claims abstract description 19
- 230000002496 gastric effect Effects 0.000 claims abstract description 14
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 13
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 13
- 229940111202 pepsin Drugs 0.000 claims abstract description 13
- 230000028993 immune response Effects 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 208000026935 allergic disease Diseases 0.000 claims abstract description 4
- 108091005804 Peptidases Proteins 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 239000000853 adhesive Substances 0.000 claims description 14
- 230000001070 adhesive effect Effects 0.000 claims description 14
- 102000004142 Trypsin Human genes 0.000 claims description 12
- 108090000631 Trypsin Proteins 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 12
- 238000006460 hydrolysis reaction Methods 0.000 claims description 12
- 239000012588 trypsin Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 208000009793 Milk Hypersensitivity Diseases 0.000 claims description 6
- 201000010859 Milk allergy Diseases 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 3
- 230000004888 barrier function Effects 0.000 claims description 3
- 230000003614 tolerogenic effect Effects 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000000112 colonic effect Effects 0.000 claims 1
- 230000031599 regulation of hypersensitivity Effects 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 10
- 208000010668 atopic eczema Diseases 0.000 abstract description 9
- 241000283690 Bos taurus Species 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 235000013336 milk Nutrition 0.000 abstract description 4
- 239000008267 milk Substances 0.000 abstract description 4
- 210000004080 milk Anatomy 0.000 abstract description 4
- 239000013566 allergen Substances 0.000 abstract description 3
- 230000000172 allergic effect Effects 0.000 abstract description 3
- 230000007358 intestinal barrier function Effects 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000037213 diet Effects 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract description 2
- 238000003379 elimination reaction Methods 0.000 abstract description 2
- 230000001771 impaired effect Effects 0.000 abstract description 2
- 230000029087 digestion Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000413 hydrolysate Substances 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 239000005018 casein Substances 0.000 description 48
- 102000011632 Caseins Human genes 0.000 description 40
- 108010076119 Caseins Proteins 0.000 description 40
- 235000021240 caseins Nutrition 0.000 description 38
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 29
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 13
- 206010012438 Dermatitis atopic Diseases 0.000 description 13
- 201000008937 atopic dermatitis Diseases 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 235000020247 cow milk Nutrition 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 102000004388 Interleukin-4 Human genes 0.000 description 10
- 108090000978 Interleukin-4 Proteins 0.000 description 10
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 10
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 10
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 10
- 206010003645 Atopy Diseases 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 210000003608 fece Anatomy 0.000 description 8
- 239000005862 Whey Substances 0.000 description 7
- 102000007544 Whey Proteins Human genes 0.000 description 7
- 108010046377 Whey Proteins Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 208000004262 Food Hypersensitivity Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010016946 Food allergy Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000007065 protein hydrolysis Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940021722 caseins Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000020932 food allergy Nutrition 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 235000021249 α-casein Nutrition 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000024833 regulation of cytokine production Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
- A23J3/344—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins of casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI952926A FI104465B (fi) | 1995-06-14 | 1995-06-14 | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| PCT/FI1996/000350 WO1997000078A1 (en) | 1995-06-14 | 1996-06-12 | Methods of preventing or treating allergies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG102144A BG102144A (en) | 1998-12-30 |
| BG63153B1 true BG63153B1 (bg) | 2001-05-31 |
Family
ID=8543602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG102144A BG63153B1 (bg) | 1995-06-14 | 1997-12-23 | Метод за получаване на протеинов хидролизат и използването му за предотвратяване или лечение на алергии |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6506380B1 (enExample) |
| EP (1) | EP0833649B2 (enExample) |
| JP (1) | JP3983804B2 (enExample) |
| KR (1) | KR100494741B1 (enExample) |
| CN (1) | CN1154506C (enExample) |
| AR (1) | AR003960A1 (enExample) |
| AT (1) | ATE230606T1 (enExample) |
| BG (1) | BG63153B1 (enExample) |
| BR (1) | BR9607827A (enExample) |
| CA (1) | CA2224320C (enExample) |
| CZ (1) | CZ291904B6 (enExample) |
| DE (1) | DE69625690T3 (enExample) |
| DK (1) | DK0833649T4 (enExample) |
| EE (1) | EE03424B1 (enExample) |
| ES (1) | ES2191103T5 (enExample) |
| FI (1) | FI104465B (enExample) |
| IL (1) | IL122577A0 (enExample) |
| MX (1) | MX9710109A (enExample) |
| MY (1) | MY113912A (enExample) |
| NO (1) | NO321504B1 (enExample) |
| NZ (1) | NZ310478A (enExample) |
| PL (1) | PL185123B1 (enExample) |
| RO (1) | RO120243B1 (enExample) |
| SK (1) | SK284245B6 (enExample) |
| WO (1) | WO1997000078A1 (enExample) |
| ZA (1) | ZA965088B (enExample) |
Families Citing this family (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| AU750136B2 (en) * | 1997-06-03 | 2002-07-11 | Ganeden Biotech, Inc. | Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS |
| JP2002534966A (ja) | 1999-01-19 | 2002-10-22 | マキシジェン， インコーポレイテッド | オリゴヌクレオチド媒介核酸組換え |
| EP1206523B1 (en) | 1999-08-05 | 2009-03-11 | Société des Produits Nestlé S.A. | Bifidobacteria preventing diarrhea caused by pathogenic bacteria |
| US6998119B1 (en) | 1999-08-05 | 2006-02-14 | Nestec S.A. | Feed composition containing Bifidobacterium CNCM 1-2168 capable of preventing diarrhea |
| AU2001234784A1 (en) * | 2000-02-04 | 2001-08-14 | Bioseek | Compositions and methods for reducing autoimmunity |
| FI110668B (fi) * | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
| EP1379635A2 (en) * | 2000-09-25 | 2004-01-14 | Societe Des Produits Nestle S.A. | Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions |
| CN100553646C (zh) * | 2000-10-06 | 2009-10-28 | 雀巢产品股份有限公司 | 用乳酸菌微生态制剂调节皮肤免疫系统 |
| FI109602B (fi) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
| EP1228707A1 (en) * | 2001-02-01 | 2002-08-07 | Campina Melkunie B.V. | Use of alpha-lactalbumin as prebiotic agent |
| JP2004519241A (ja) * | 2001-03-09 | 2004-07-02 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | 高齢化に伴う生理的障害を改善し寿命を延ばす組成物 |
| JP2003137804A (ja) * | 2001-10-31 | 2003-05-14 | Morinaga Milk Ind Co Ltd | インターロイキン−１８誘導剤 |
| EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
| WO2003102195A1 (en) | 2002-06-04 | 2003-12-11 | Dsm Ip Assets B.V. | Protein hydrolysate rich in tripeptides |
| DK1565547T4 (da) | 2002-06-28 | 2013-01-14 | Biosearch S A | Probiotiske stammer, en fremgangsmåde til selektion deraf, præparater deraf samt anvendelse deraf |
| EP1384483A1 (en) | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
| US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
| US20040208863A1 (en) * | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
| PT1638416E (pt) * | 2003-06-23 | 2013-07-08 | Nestec Sa | Utilização de uma fórmula nutricional para função de barreira intestinal óptima |
| ES2552053T3 (es) | 2004-02-25 | 2015-11-25 | Pioneer Hi-Bred International Inc. | Nuevos polipéptidos cristalinos de Bacillus thuringiensis, polinucleótidos, y composiciones de los mismos |
| US20050265946A1 (en) * | 2004-05-28 | 2005-12-01 | Kao Corporation | Elastase inhibitor |
| US7862808B2 (en) * | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
| EP2108269A1 (en) | 2005-04-13 | 2009-10-14 | Nestec S.A. | Infant formula with low dose probiotics and low dose proteins |
| US7303745B2 (en) | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| US20060233762A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
| EP1951064B2 (en) * | 2005-11-14 | 2020-05-13 | Société des Produits Nestlé S.A. | Oral tolerance promotion with glycated proteins |
| ES2381211T3 (es) | 2006-02-15 | 2012-05-24 | Nestec S.A. | Uso del Bifidobacterium longum para prevenir y tratar inflamaciones |
| ES2553636T3 (es) | 2006-03-07 | 2015-12-10 | Nestec S.A. | Mezcla simbiótica |
| CA2653157A1 (en) * | 2006-06-15 | 2007-12-21 | Nestec S.A. | Induction of tolerance to egg proteins |
| CN105796607A (zh) * | 2007-02-28 | 2016-07-27 | Mjn 美国控股有限责任公司 | 用于儿童或婴幼儿的含有灭活益生菌的产品 |
| EP1974735A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Reduction of risk of diarrhoea |
| CN101273737B (zh) * | 2007-03-28 | 2011-08-24 | 哈尔滨正方科技有限公司 | 一种在常温下保持高活菌数的发酵乳饮料的制备方法 |
| EP1974734A1 (en) † | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
| EP1974743A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
| CN101784669B (zh) | 2007-08-24 | 2015-02-18 | 科德克希思公司 | 用于(r)-3-羟基四氢噻吩的立体选择性制备的改善的酮还原酶多肽 |
| EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
| WO2009092628A1 (en) | 2008-01-24 | 2009-07-30 | Nestec S.A. | Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule |
| ES2950396T3 (es) | 2008-02-01 | 2023-10-09 | Prota Therapeutics Pty Ltd | Un método para inducir tolerancia a un alérgeno |
| EP2265135B1 (en) | 2008-03-14 | 2017-12-20 | Nestec S.A. | Synbiotic mixture |
| EP2127661A1 (en) | 2008-05-27 | 2009-12-02 | Nestec S.A. | Probiotics to improve gut microbiotica |
| US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| HUE029228T2 (en) | 2008-06-13 | 2017-02-28 | Codexis Inc | A method for the synthesis of polynucleotide variants |
| JP2011525533A (ja) | 2008-06-24 | 2011-09-22 | コデクシス， インコーポレイテッド | 実質的に立体異性的に純粋な縮合二環式プロリン化合物の調製のための生体触媒法 |
| EP2147678A1 (en) | 2008-07-21 | 2010-01-27 | Nestec S.A. | Probiotics to increase IgA secretion in infants born by caesarean section |
| RU2392001C2 (ru) * | 2008-08-04 | 2010-06-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ лечения желтушных форм вирусного гепатита а у детей с пищевой аллергией |
| SI2329013T1 (sl) | 2008-08-27 | 2016-03-31 | Codexis, Inc. | Polipeptidi ketoreduktaze za proizvodnjo 3-aril-3-hidroksipropanamina iz 3-aril-3-ketopropanamina |
| US8470564B2 (en) | 2009-01-08 | 2013-06-25 | Codexis, Inc. | Transaminase polypeptides |
| BRPI1013886A2 (pt) | 2009-03-17 | 2016-10-11 | Codexis Inc | variantes de endoglucanases, polinucleotídeos e usos a elas relacionados |
| BRPI1010239A2 (pt) | 2009-03-31 | 2016-10-11 | Codexis Inc | endoglucanases aprimoradas, derivados e seus usos |
| EP2443139B1 (en) | 2009-06-16 | 2016-08-10 | Codexis, Inc. | Beta-glucosidase variant enzymes and related polynucleotides |
| EP2446025B1 (en) | 2009-06-22 | 2018-08-08 | Codexis, Inc. | Ketoreductase-mediated stereoselective route to alpha chloroalcohols |
| WO2011011630A2 (en) | 2009-07-23 | 2011-01-27 | Codexis, Inc. | Nitrilase biocatalysts |
| ES2518490T3 (es) * | 2009-08-18 | 2014-11-05 | Nestec S.A. | Una composición nutritiva, la cual comprende cepas de Lactococcus y que reduce los síntomas de alergia, especialmente, en lactantes y en niños |
| AU2010285128B2 (en) * | 2009-08-18 | 2015-05-14 | Société des Produits Nestlé S.A. | A nutritional composition comprising Bifidobacterium longum strains and reducing food allergy symtoms, especially in infants and children |
| WO2011022548A2 (en) | 2009-08-19 | 2011-02-24 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
| CA2772859C (en) | 2009-09-04 | 2015-05-26 | Codexis, Inc. | Variant cbh2 cellulases and related polynucleotides |
| EP2295535A1 (en) * | 2009-09-11 | 2011-03-16 | Mead Johnson Nutrition Company | Probiotic material |
| SG179197A1 (en) | 2009-09-18 | 2012-04-27 | Codexis Inc | Reduced codon mutagenesis |
| BR112012012192A2 (pt) | 2009-11-25 | 2017-07-04 | Codexis Inc | b-glicosidades variantes recombinantes thermoascus aurantiacus para produção de açúcares fermentáveis a partir da biomassa celulósica |
| EP2706119B1 (en) | 2009-11-25 | 2015-08-12 | Codexis, Inc. | Recombinant beta-glucosidase variants for production of soluble sugars from cellulosic biomass |
| EP2510089B1 (en) | 2009-12-08 | 2015-10-21 | Codexis, Inc. | Synthesis of prazole compounds |
| US9226521B2 (en) | 2009-12-08 | 2016-01-05 | Nestec S.A. | Infant formula with probiotics and milk fat globule membrane components |
| CA2786001A1 (en) | 2009-12-31 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
| US9040262B2 (en) | 2010-05-04 | 2015-05-26 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
| JP2013528374A (ja) | 2010-05-10 | 2013-07-11 | パーシード セラピューティクス リミテッド ライアビリティ カンパニー | Ｖｌａ４のポリペプチド阻害剤 |
| EP2576804B1 (en) | 2010-05-28 | 2016-12-14 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| WO2011159910A2 (en) | 2010-06-17 | 2011-12-22 | Codexis, Inc. | Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol |
| CA2804019A1 (en) | 2010-06-28 | 2012-01-12 | Codexis, Inc. | Fatty alcohol forming acyl reductases (fars) and methods of use thereof |
| WO2012003299A2 (en) | 2010-06-30 | 2012-01-05 | Codexis, Inc. | Highly stable beta-class carbonic anhydrases useful in carbon capture systems |
| CA2808098C (en) | 2010-08-16 | 2020-03-10 | Merck Sharp & Dohme Corp. | Process for preparing aminocyclohexyl ether compounds |
| EP2606131B1 (en) | 2010-08-20 | 2017-03-08 | Codexis, Inc. | Use of glycoside hydrolase 61 family proteins in processing of cellulose |
| HUE037616T2 (hu) | 2010-12-08 | 2018-09-28 | Codexis Inc | Biokatalizátorok és eljárások armodafinil szintéziséhez |
| EE05750B1 (et) | 2011-02-25 | 2015-06-15 | OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isoleeritud mikroorganismi tüvi Lactobacillus gasseri MCC2 DSM 23882 ning selle kasutamine |
| WO2012135110A1 (en) | 2011-03-30 | 2012-10-04 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| DK2697662T3 (en) | 2011-04-13 | 2018-07-30 | Codexis Inc | BIOCATALYTIC PROCEDURE FOR PREPARING ESLICARBAZEPIN AND ANALOGUES THEREOF |
| UA111078C2 (uk) * | 2011-05-03 | 2016-03-25 | Нестек С.А. | Гідролізат білкового субстрату і спосіб його виготовлення |
| WO2013003219A1 (en) | 2011-06-30 | 2013-01-03 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| BR112014004171A2 (pt) | 2011-08-22 | 2018-11-06 | Codexis Inc | variantes da proteína glicósideo hidrolase gh61 e cofatores que aumentam a atividade de gh61 |
| CN103998461B (zh) | 2011-09-08 | 2018-02-02 | 科德克希思公司 | 用于合成取代的内酰胺的生物催化剂和方法 |
| BR112014007719A2 (pt) | 2011-09-30 | 2017-06-13 | Codexis Inc | proteases fúngicas |
| US20130084271A1 (en) * | 2011-10-03 | 2013-04-04 | Kelly Foods Corporation | Probiotic composition for pets and method of providing the same |
| US20130089638A1 (en) * | 2011-10-11 | 2013-04-11 | Mead Johnson Nutrition Company | Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes |
| CN104053771B (zh) | 2011-11-18 | 2016-11-09 | 科德克希思公司 | 用于制备羟基取代的氨基甲酸酯的生物催化剂 |
| US9611462B2 (en) | 2011-12-20 | 2017-04-04 | Codexis, Inc. | Endoglucanase 1B (EG1B) variants |
| WO2013142770A1 (en) | 2012-03-23 | 2013-09-26 | Codexis, Inc. | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs |
| US20130251829A1 (en) * | 2012-03-23 | 2013-09-26 | Mead Johnson Nutrition Company | Probiotic derived non-viable material for infection prevention and treatment |
| DK2847327T3 (en) | 2012-05-08 | 2019-03-11 | Codexis Inc | BIO-CATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS |
| US9193957B2 (en) | 2012-05-11 | 2015-11-24 | Codexis, Inc. | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds |
| WO2013188305A2 (en) | 2012-06-11 | 2013-12-19 | Codexis, Inc. | Fungal beta-xylosidase variants |
| WO2014081605A1 (en) | 2012-11-20 | 2014-05-30 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| EP3406594A1 (en) | 2012-12-07 | 2018-11-28 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| CN105008528A (zh) | 2012-12-21 | 2015-10-28 | 科德克希思公司 | 用于合成手性胺的工程化的生物催化剂和方法 |
| US9540622B2 (en) | 2013-01-18 | 2017-01-10 | Codexis, Inc. | Engineered biocatalysts useful for carbapenem synthesis |
| SI2961844T1 (sl) | 2013-02-28 | 2018-11-30 | Codexis, Inc. | Spremenjeni polipeptidi transaminaze za industrijsko biokatalizo |
| CN103355405A (zh) * | 2013-04-07 | 2013-10-23 | 苏州旭优食品科技有限公司 | 一种低过敏性含乳制品的加工工艺 |
| SG11201508598YA (en) | 2013-04-18 | 2015-11-27 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
| HUE053379T2 (hu) | 2013-11-13 | 2021-06-28 | Codexis Inc | Génmódosított imin-reduktázok és eljárások keton és amin vegyületek reduktív aminálására |
| DK3145536T3 (da) | 2014-04-16 | 2022-01-03 | Codexis Inc | Modificeret tyrosinammoniaklyase |
| EP3167052B1 (en) | 2014-07-09 | 2020-01-01 | Codexis, Inc. | P450-bm3 variants with improved activity |
| CA2968275C (en) | 2014-11-25 | 2023-09-12 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| KR102438885B1 (ko) | 2014-12-22 | 2022-09-01 | 코덱시스, 인코포레이티드 | 인간 알파-갈락토시다제 변이체 |
| US10696953B2 (en) | 2015-02-10 | 2020-06-30 | Codexis, Inc. | Ketoreductase polypeptides for the synthesis of chiral compounds |
| EP3292136B1 (en) | 2015-05-07 | 2021-02-17 | Codexis, Inc. | Penicillin-g acylases |
| CN108271374B (zh) | 2015-07-07 | 2021-09-21 | 科德克希思公司 | 具有改进的活性的新颖p450-bm3变体 |
| US10724025B2 (en) | 2016-05-05 | 2020-07-28 | Codexis, Inc. | Penicillin-G acylases |
| WO2017213758A1 (en) | 2016-06-09 | 2017-12-14 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
| SG11201810998WA (en) | 2016-06-15 | 2019-01-30 | Codexis Inc | Engineered beta-glucosidases and glucosylation methods |
| EP4223766A3 (en) | 2016-08-26 | 2023-10-18 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| KR102696584B1 (ko) | 2017-01-05 | 2024-08-19 | 코덱시스, 인코포레이티드 | 페니실린 ｇ 아실라아제 |
| IL321402A (en) | 2017-02-03 | 2025-08-01 | Tate & Lyle Solutions Usa Llc | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
| NZ755628A (en) | 2017-02-13 | 2023-09-29 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| CA3061133A1 (en) | 2017-04-27 | 2018-11-01 | Codexis, Inc. | Ketoreductase polypeptides and polynucleotides |
| EP3635101B1 (en) | 2017-05-08 | 2021-08-18 | Codexis, Inc. | Engineered ligase variants |
| CN111032682B (zh) | 2017-06-14 | 2024-04-12 | 科德克希思公司 | 用于工业生物催化的工程化转氨酶多肽 |
| EP3645713A4 (en) | 2017-06-27 | 2021-06-30 | Codexis, Inc. | PENICILLIN-G ACYLASES |
| US10793841B2 (en) | 2017-06-30 | 2020-10-06 | Codexis, Inc. | T7 RNA polymerase variants |
| JP2020530267A (ja) | 2017-06-30 | 2020-10-22 | コデクシス， インコーポレイテッド | Ｔ７ ｒｎａポリメラーゼバリアント |
| CA3080512A1 (en) | 2017-11-07 | 2019-05-16 | Codexis, Inc. | Transglutaminase variants |
| WO2019116311A1 (en) | 2017-12-13 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Carboxyesterase biocatalysts |
| SG11202004185PA (en) | 2017-12-13 | 2020-06-29 | Codexis Inc | Carboxyesterase polypeptides for amide coupling |
| US10900055B2 (en) | 2018-06-12 | 2021-01-26 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| MX2021000328A (es) | 2018-07-09 | 2021-03-25 | Codexis Inc | Enzimas de variantes de galactosa oxidasa modificadas geneticamente. |
| KR20210032417A (ko) | 2018-07-09 | 2021-03-24 | 코덱시스, 인코포레이티드 | 조작된 데옥시리보스-포스페이트 알돌라아제 |
| CA3103819A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered pantothenate kinase variant enzymes |
| EP3821026A4 (en) | 2018-07-09 | 2022-06-01 | Codexis, Inc. | MANIPULATED ENZYME VARIANTS OF PHOSPHOPENTOMUTASE |
| US11162105B2 (en) | 2018-07-09 | 2021-11-02 | Codexis, Inc. | Engineered purine nucleoside phosphorylase variant enzymes |
| CA3105916A1 (en) | 2018-07-12 | 2020-01-16 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| MX2021001260A (es) | 2018-07-30 | 2021-04-12 | Tate & Lyle Solutions Usa Llc | Glucosiltransferasas modificadas con ingenieria genetica y metodos de glucosilacion de glucosido de esteviol. |
| EP3874033A4 (en) | 2018-10-29 | 2022-08-03 | Codexis, Inc. | ENGINEERED DNA POLYMERASE VARIANTS |
| US11473077B2 (en) | 2018-12-14 | 2022-10-18 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| CN113544268A (zh) | 2018-12-20 | 2021-10-22 | 科德克希思公司 | 人类α半乳糖苷酶变体 |
| SG11202110852RA (en) | 2019-05-01 | 2021-10-28 | Codexis Inc | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| US12215359B2 (en) | 2019-05-01 | 2025-02-04 | Codexis, Inc. | Engineered glucose dehydrogenases and methods for the reductive amination of ketone and amine compounds |
| US12275962B2 (en) | 2019-07-02 | 2025-04-15 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
| KR20220028053A (ko) | 2019-07-02 | 2022-03-08 | 코덱시스, 인코포레이티드 | 조작된 수크로스 포스포릴라제 변이체 효소 |
| ES2983662T3 (es) | 2019-07-23 | 2024-10-24 | Frieslandcampina Nederland Bv | Composición nutricional que comprende grasa láctea e inmunoglobulina |
| US11987823B2 (en) | 2019-08-30 | 2024-05-21 | Societe Des Produits Nestle S.A. | Engineered lipase variants |
| CA3149870A1 (en) | 2019-09-12 | 2021-03-18 | Codexis, Inc. | Peroxidase activity towards 10-acetyl-3,7-dihydroxyphenoxazine |
| AU2020358714A1 (en) | 2019-10-02 | 2022-05-12 | Abbott Diabetes Care Inc. | Detection of analytes by protein switches |
| WO2021108209A1 (en) | 2019-11-26 | 2021-06-03 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
| WO2021127457A1 (en) | 2019-12-20 | 2021-06-24 | Codexis, Inc. | Engineered acid alpha-glucosidase variants |
| CA3168922A1 (en) | 2020-02-04 | 2021-08-12 | Codexis, Inc. | Engineered leucine decarboxylases |
| CA3179751A1 (en) | 2020-04-10 | 2021-10-14 | Codexis, Inc. | Engineered transaminase polypeptides |
| JP2023539632A (ja) | 2020-08-28 | 2023-09-15 | コデクシス， インコーポレイテッド | 操作されたプロテアーゼバリアント |
| MX2023002421A (es) | 2020-08-28 | 2023-05-18 | Codexis Inc | Variantes de amilasa modificadas geneticamente. |
| EP4259772A1 (en) | 2020-12-11 | 2023-10-18 | Willow Biosciences, Inc. | Recombinant acyl activating enzyme (aae) genes for enhanced biosynthesis of cannabinoids and cannabinoid precursors |
| EP4262804A4 (en) | 2020-12-18 | 2025-02-12 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
| CA3214973A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered guanylate kinase variant enzymes |
| IL305924B2 (en) | 2021-04-02 | 2025-09-01 | Codexis Inc | Engineered Cyclic GMP-AMP Synthase (CGAS) Variant Enzymes |
| US11913037B2 (en) | 2021-04-02 | 2024-02-27 | Codexis, Inc. | Engineered adenylate kinase variant enzymes |
| CA3215105A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
| AU2022279241A1 (en) | 2021-05-21 | 2023-11-30 | Codexis, Inc. | Engineered methionine gamma lyase variants |
| EP4377451A2 (en) | 2021-07-30 | 2024-06-05 | Willow Biosciences, Inc. | Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| WO2023023621A1 (en) | 2021-08-19 | 2023-02-23 | Willow Biosciences, Inc. | Recombinant olivetolic acid cyclase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| WO2023064938A1 (en) | 2021-10-15 | 2023-04-20 | Codexis, Inc. | Engineered dna polymerase variants |
| WO2023069921A1 (en) | 2021-10-19 | 2023-04-27 | Epimeron Usa, Inc. | Recombinant thca synthase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| DE112023000593T5 (de) | 2022-03-31 | 2024-11-14 | Qingdao Kingagroot Chemical Compound Co., Ltd. | Monoaminoxidase und deren anwendung |
| WO2024040020A1 (en) | 2022-08-15 | 2024-02-22 | Absci Corporation | Quantitative affinity activity specific cell enrichment |
| CN120981566A (zh) | 2023-01-12 | 2025-11-18 | 诺华股份有限公司 | 工程化酮还原酶多肽 |
| WO2025061911A1 (en) | 2023-09-22 | 2025-03-27 | Glaxosmithkline Intellectual Property Development Limited | Methods of producing nucleotide triphosphates (ntps) |
| WO2025144700A1 (en) | 2023-12-27 | 2025-07-03 | Absci Corporation | Nanobody library screening using bacterial surface display |
| WO2025235589A1 (en) | 2024-05-08 | 2025-11-13 | Codexis, Inc. | Dna polymerase variants |
| WO2025242702A1 (en) | 2024-05-23 | 2025-11-27 | Glaxosmithkline Intellectual Property Development Limited | Enzymatic process for producing n-acetyl galactosamine clusters |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3886288A (en) * | 1970-06-15 | 1975-05-27 | Swift & Co | Cheese manufacture using highly active proteolytic enzymes |
| JPS5279086A (en) | 1975-12-25 | 1977-07-02 | Nippon Soda Co Ltd | Preparation of antibiotic tunicamycin |
| JPS5279083A (en) * | 1975-12-26 | 1977-07-02 | Morinaga Milk Industry Co Ltd | Production of protein decomposed substance not having bitterness and antigen property |
| JPS6041751B2 (ja) | 1976-06-22 | 1985-09-18 | ジエコ−株式会社 | デジタル電子時計 |
| JPS548785A (en) | 1977-06-21 | 1979-01-23 | Kikkoman Corp | Preparation of protein hydrolyzate |
| US4839281A (en) † | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| DK589785A (da) * | 1985-12-18 | 1987-06-19 | Samuelsson Ernst Gunnar | Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet |
| ATE84680T1 (de) † | 1987-12-23 | 1993-02-15 | Nestle Sa | Verfahren zur herstellung eines molkeeiweisshydrolysates und eines hypoallergenen nahrungsmittels. |
| DD281540A5 (de) * | 1988-08-08 | 1990-08-15 | Berlin Chemie Veb | Verfahren zur herstellung von nutritiva |
| ES2063882T5 (es) † | 1989-10-02 | 2001-12-01 | Novartis Nutrition Ag | Hidrolizados de proteinas. |
| JP3071877B2 (ja) † | 1991-06-27 | 2000-07-31 | 財団法人糧食研究会 | 経口寛容誘導能を有する低アレルゲン性酵素分解ペプチド組成物 |
| US5952034A (en) * | 1991-10-12 | 1999-09-14 | The Regents Of The University Of California | Increasing the digestibility of food proteins by thioredoxin reduction |
| EP0577903B1 (fr) * | 1992-07-06 | 1997-12-17 | Societe Des Produits Nestle S.A. | Agent antigastrite |
| FI94089C (fi) | 1992-12-10 | 1995-07-25 | Valio Oy | Menetelmä allergiaa aiheuttavien yhdisteiden poistamiseksi proteiinipitoisista koostumuksista |
| RU2031586C1 (ru) | 1993-02-05 | 1995-03-27 | Тамара Георгиевна Извекова | Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения |
| GB9312369D0 (en) | 1993-06-16 | 1993-07-28 | Sandoz Nutrition Ltd | Organic compounds |
| AU1076595A (en) † | 1993-11-23 | 1995-06-13 | Kabushiki Kaisha Wado Doctors Group | Intestinal flora improver composition, and apparatus and system for producing the same |
| FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
-
1995
- 1995-06-14 FI FI952926A patent/FI104465B/fi not_active IP Right Cessation
-
1996
- 1996-06-11 MY MYPI96002357A patent/MY113912A/en unknown
- 1996-06-12 EE EE9700339A patent/EE03424B1/xx unknown
- 1996-06-12 RO RO97-02328A patent/RO120243B1/ro unknown
- 1996-06-12 KR KR1019970709383A patent/KR100494741B1/ko not_active Expired - Lifetime
- 1996-06-12 EP EP96918707A patent/EP0833649B2/en not_active Expired - Lifetime
- 1996-06-12 BR BR9607827-8A patent/BR9607827A/pt not_active Application Discontinuation
- 1996-06-12 ES ES96918707T patent/ES2191103T5/es not_active Expired - Lifetime
- 1996-06-12 US US08/973,963 patent/US6506380B1/en not_active Expired - Lifetime
- 1996-06-12 DE DE69625690T patent/DE69625690T3/de not_active Expired - Lifetime
- 1996-06-12 NZ NZ310478A patent/NZ310478A/xx not_active IP Right Cessation
- 1996-06-12 AT AT96918707T patent/ATE230606T1/de active
- 1996-06-12 CA CA2224320A patent/CA2224320C/en not_active Expired - Lifetime
- 1996-06-12 WO PCT/FI1996/000350 patent/WO1997000078A1/en not_active Ceased
- 1996-06-12 SK SK1715-97A patent/SK284245B6/sk not_active IP Right Cessation
- 1996-06-12 CZ CZ19973997A patent/CZ291904B6/cs not_active IP Right Cessation
- 1996-06-12 PL PL96324010A patent/PL185123B1/pl unknown
- 1996-06-12 CN CNB961947527A patent/CN1154506C/zh not_active Expired - Lifetime
- 1996-06-12 IL IL12257796A patent/IL122577A0/xx not_active IP Right Cessation
- 1996-06-12 JP JP50267197A patent/JP3983804B2/ja not_active Expired - Lifetime
- 1996-06-12 DK DK96918707T patent/DK0833649T4/da active
- 1996-06-13 AR ARP960103134A patent/AR003960A1/es unknown
- 1996-06-14 ZA ZA965088A patent/ZA965088B/xx unknown
-
1997
- 1997-12-11 NO NO19975832A patent/NO321504B1/no not_active IP Right Cessation
- 1997-12-11 MX MX9710109A patent/MX9710109A/es unknown
- 1997-12-23 BG BG102144A patent/BG63153B1/bg unknown
-
2002
- 2002-12-18 US US10/321,661 patent/US7172756B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG63153B1 (bg) | Метод за получаване на протеинов хидролизат и използването му за предотвратяване или лечение на алергии | |
| Sütas et al. | Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG–derived enzymes | |
| Majamaa et al. | Probiotics: a novel approach in the management of food allergy | |
| Sashihara et al. | An analysis of the effectiveness of heat-killed lactic acid bacteria in alleviating allergic diseases | |
| RU2522282C2 (ru) | Применение штамма вifidobacterium для получения композиции, предназначенной для профилактики и/или лечения проявлений аллергического типа | |
| RU2262943C2 (ru) | Сомногенная активность непатогенных молочно-кислых бактерий | |
| Prioult et al. | Allergenicity of acidic peptides from bovine β-lactoglobulin is reduced by hydrolysis with Bifidobacterium lactis NCC362 enzymes | |
| Pescuma et al. | Hydrolysate of β-lactoglobulin by Lactobacillus delbrueckii subsp. bulgaricus CRL 656 suppresses the immunoreactivity of β-lactoglobulin as revealed by in vivo assays | |
| US6506388B1 (en) | Immunomodulator, immunomodulator food | |
| JP2968374B2 (ja) | ＩｇＡ産生促進剤 | |
| Hodgkinson et al. | Effect of raw milk on allergic responses in a murine model of gastrointestinal allergy | |
| RU2174012C2 (ru) | Способы профилактики или лечения аллергии | |
| AU710126C (en) | Methods of preventing or treating allergies | |
| HK1010081B (en) | Methods of preventing or treating allergies | |
| Crane | Pro and anti: the biotics of allergic disease |